Stock SEQUA SEQUANA MEDICAL N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Sequana Medical N.V.

Equities

SEQUA

BE0974340722

Market Closed - Euronext Bruxelles
Other stock markets
 16:35:07 10/05/2024 BST 		5-day change 1st Jan Change
1.49 EUR 0.00% Intraday chart for Sequana Medical N.V. +1.71% -62.75%
04-03 Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure CI
03-28 Sequana Medical NV Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure
CI
Sequana Medical NV Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sequana Medical NV Announces Three Month Follow-Up Data from MOJAVE Non- Randomized Cohort Confirming Significant Improvement in Diuretic Response and Virtual Elimination of Loop Diuretics Following DSR Therapy
CI
Sequana Medical Raises EUR11.5 Million via Share Placement
MT
Sequana Medical Receives New US Reimbursement Codes for Alfapump System
MT
Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure
CI
Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome
CI
Sequana Medical NV Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure
CI
Sequana Medical NV Announces Completion of 1,000th Alfapump Implant
CI
Sequana Medical NV Announces Submission of Investigational New Drug Application for DSR® 2.0 for Treatment of Congestive Heart Failure
CI
Sequana Medical Receives US, Chinese Patents for Direct Sodium Removal Program
MT
Sequana Medical Announces Positive Results from Chihuahua, Phase 1 Clinical Trial of Second-Generation DSR Product for Congestive Heart Failure
CI
Sequana Medical NV Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Sequana Medical Announces Successful Completion of Pre-Clinical Studies with its Second-Generation DSR Product for Congestive Heart Failure
CI
Sequana Medical NV Announces Positive Top-Line Results from SAHARA Ph. 2a Study of DSR 1.0 in Diuretic-Resistant Heart Failure Patients with Persistent Congestion and First Patient Dosed Successfully with DSR 2.0 in YUKON
CI
Sequana Medical NV Announces Positive Top-Line Results from the North American Pivotal POSEIDON study of the alfapump
CI
Sequana Medical NV Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR, Reports Disease-Modifying Profile for Short Term DSR
CI
Sequana Medical N : Statutory auditor’s report on the Bootstrap Warrants
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SEQUA Stock
  4. News Sequana Medical N.V.
  5. Highlights